CompletedPhase 3NCT00262769
Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
Studying Carcinoma of gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- John A. BridgewaterUniversity College London (UCL) Cancer Institute
- Intervention
- cisplatin(drug)
- Enrollment
- 324 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2005
Study locations (25)
- Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
- Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Cumberland Infirmary, Carlisle, England, United Kingdom
- Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
- Derbyshire Royal Infirmary, Derby, England, United Kingdom
- Princess Alexandra Hospital, Essex, England, United Kingdom
- Gloucestershire Royal Hospital, Gloucester, England, United Kingdom
- Princess Royal Hospital at Hull and East Yorkshire NHS Trust, Hull, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
- Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom
- Royal Marsden - London, London, England, United Kingdom
- Hammersmith Hospital, London, England, United Kingdom
- UCL Cancer Institute, London, England, United Kingdom
- University College of London Hospitals, London, England, United Kingdom
- +10 more locations on ClinicalTrials.gov
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00262769 on ClinicalTrials.govOther trials for Carcinoma of gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06901622Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaThe First Affiliated Hospital of Zhengzhou University
- RECRUITINGNCT07337850Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersTata Memorial Centre
- RECRUITINGPHASE2NCT06440993Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- ACTIVE NOT RECRUITINGPHASE2NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsLisata Therapeutics, Inc.
- ENROLLING BY INVITATIONPHASE3NCT06671418Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary ObstructionErasmus Medical Center
- RECRUITINGNCT05404347NGS in Gallbladder Cancer and Response to TreatmentBanaras Hindu University
See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →